Overview

Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma

Status:
Unknown status

Trial end date:
2016-12-01

Target enrollment:
0

Participant gender:
All

Summary

The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Zhejiang Cancer Hospital

Collaborators:

Second Affiliated Hospital, School of Medicine, Zhejiang University
Sir Run Run Shaw Hospital
Zhejiang University

Treatments:

Cisplatin
Endostatins
Gemcitabine

Criteria

Inclusion Criteria:

- metastatic nasopharyngeal carcinoma 6 months after first treatment,never receive any
anticancer treatment except local radiotherapy to the bone metastasis，at least one
measurable metastatic lesions，ECOG PS 0-1，Electrocardiogram (ecg) no special
abnormal，comply with the test requirements, cooperate with regular follow-up.

Exclusion Criteria:

- To give local treatment,clinical severe infection(>grade 2),with the central nervous
system metastases,ECOG PS≥2,patients with pregnancy or breastfeeding,has a history of
peripheral nerve disease,concomitant with other serious diseases,ever or concomitant
with other serious diseases except for Cervical carcinoma in situ,cure of basal cell
carcinoma,bladder surface tumor,any cancer 3 years after curation.